Massachusetts Institute of Technology
Sign in Create Account

Defining the Challenges Surrounding Innovation and Safety (Part One)

08/18/2005 8:30 AM Wong Auditorium
Frank L. Douglas, Executive Director, MIT Center for Biomedical Innovation; Professor of the Practice; Una Ryan, President & CEO, AVANT Immunotherapeutics, Inc.; Robert Tepper, President, Research and Development ; Millennium Pharmaceuticals; John A. Fallon, Chief Physician Executive and Senior Vice President, Blue Cross Blue Shield of Massachusetts ; Ernst R. Berndt, Louis B. Seley Professor of Applied Economics, MIT Sloan School of Management

Description: Recent scrutiny of the pharmaceutical industry -- brought into sharp focus by Merck's Vioxx trial -- is leading to some big changes in the development and marketing of drugs. This panel shares deep concerns about the direction of public opinion and policy. Una Ryan's company has cooked up cost-effective vaccines that may help prevent and treat common diseases, and which can be administered orally, with a single dose, delivering quick protection. Now, new rules may demand more elaborate testing before her drugs come to market, says Ryan, with potential clinical trials running up to half a billion dollars. She says, "If we're going to have to go through ridiculous and onerous regulatory cycles, we won't be able to sell at low prices."

Robert Spiegel wonders if the new regulatory environment will continue to allow drug makers to "take chances early, and make investments taking large risks?" If the movement is "toward zero tolerance toward drug safety, and there's a frenzy to get rid of drugs with some safety issue," then the whole economic model of the industry is in peril, he says.

Robert Tepper outlines the new, "post-Vioxx" pattern, "where regulators say the job of the company is to begin risk management from the lab. As soon as we see some side effect, we must build that into our development program so we understand how it plays out." This means drawing up long-term plans involving follow-up studies and registries of every patient starting the drug. "My plea, says Tepper, is "to keep this flexible 'based on science and feasibility."

John Fallon worries that health plans like his will be playing catch-up to build electronic medical databases and physician-supported tools to help monitor drug reactions in large populations. Employer groups, already unhappy with the costs of health care, are now "saying to health plans 'where were you when Vioxx got into trouble?"

Ernst Berndt notes that with new FDA standards involving drug surveillance, "IT and engineering are becoming an important part of the drug evaluation and monitoring process," which will mean not only that databases must be standardized nationally, but internationally as well.



Host(s): Sloan School of Management, MIT Center for Biomedical Innovation

Tape #: T20182, T20183 and T20184.

Comments (0)

It looks like no one has posted a comment yet. You can be the first!

You need to log in, in order to post comments. If you don’t have an account yet, sign up now!

MIT World — special events and lectures

MIT World — special events and lectures

Category: Events | Updated 10 months ago

Created
December 12, 2011 20:30
Category
Tags
License
All Rights Reserved (What is this?)
Additional Files


Viewed
2011 times

More from MIT World — special events and lectures

Learning to See in the Dark: The Roots of Ethical Resistance

Learning to See in the Dark: The Ro...

Added over 3 years ago | 01:10:00 | 7840 views

Invention and Innovation: Emerging Technologies that Will Change the World<br> The Inventor View

Invention and Innovation: Emerging ...

Added over 3 years ago | 01:30:00 | 2911 views

MIT Perspective on Engineering Systems

MIT Perspective on Engineering Systems

Added over 3 years ago | 01:13:00 | 4237 views

A.B.L.E. Tech: Achieving Better Life Experiences for People with Injury, Disability and Aging Challenges Through 21st Century Technologies

A.B.L.E. Tech: Achieving Better Lif...

Added over 3 years ago | 01:32:00 | 5243 views

Where the Rubber Meets the Road: Why Chemomechanical Design of Materials is Critical to Sustainable Transportation Infrastructure

Where the Rubber Meets the Road: Wh...

Added over 3 years ago | 00:49:15 | 6851 views

The Institute for Soldier Nanotechnologies: Taking Nanotechnology from the Laboratory to the Soldier

The Institute for Soldier Nanotechn...

Added over 3 years ago | 00:45:19 | 2276 views